As a classical tumor-related signaling pathway, receptor tyrosine kinase (RTK) is involved in drug metabolism in many cancers, including non-small cell carcinoma, and has become a major anticancer pathway for the purpose of metabolic therapy (38). The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.